Brief: Aprea Therapeutics Announces First Patient Dosed In Phase 1 Trial Evaluating APR-1051
17/06/2024 13:44
June 17 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
ACESOT-1051
PHASE 1 TRIAL EVALUATING ORAL WEE1 INHIBITOR APR-1051
* APREA THERAPEUTICS INC: PLAN TO PROVIDE A CLINICAL UPDATE
BY
YEAR-END 2024 AND GENERATE PRELIMINARY EFFICACY DATA DURING 2025
Source text for Eikon: ID:nGNXCJbxV
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing